Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify genes related to cancer. It may also help doctors diagnose cancer and predict how patients will respond to treatment. PURPOSE: This research study is identifying cancer-related genes in blood and/or bone marrow samples from patients with acute myeloid leukemia.

Detailed Description
-----------------
OBJECTIVES: To identify and validate individual genes for diagnosis of three major translocations in acute myeloid leukemia. To correlate transcript expression data in the various translocations with age, sex, race, response to treatment, and survival and with other known mutations. OUTLINE: Blood and/or bone marrow samples previously procured from patients on CALGB-9665 are obtained from the CALGB Leukemia Tissue Bank from patients enrolled on CALGB AML treatment studies. Mononuclear cells are isolated from samples and mRNA is extracted. Gene expression profiles are analyzed via custom mRNA microarray and confirmed by quantitative real-time PCR.

Official Title
-----------------
Identification of Target Genes for Diagnosis and Prognosis of AML Using a Custom-Design Microarray

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: microarray analysis
* Genetic: polymerase chain reaction


Participation Criteria
=================
Eligibility Criteria
-----------------
Enrolled on CALGB acute myeloid leukemia (AML) treatment studies AND concurrently enrolled on Leukemia Tissue Bank Protocol CALGB-9665 Short-term or long-term survivor Bone marrow and/or peripheral blood obtained at diagnosis Leukemia is one of the following cytogenetic subtypes: t(8;21) t(15;17) inv(16)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>This is a CALGB Leukemia Tissue Bank project makes use of tissue from patients who have previously provided their consent. Diagnostic samples from patients enrolled on CALGB AML treatment studies (eg, CALGB 9621, 9710, and 19808) and who have been registered on the companion Leukemia Tissue Bank Protocol CALGB 9665 were used. | Genetic: microarray analysis<br> <br> Genetic: polymerase chain reaction<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of increased or decreased expression of same transcripts with disease outcome |  | baseline | 
| Minimum number of genes that can be used for precise diagnosis of each of the three subtypes of acute myeloid leukemia |  | baseline | 
| Identification of individual genes that are differentially expressed between the subtypes of AMLs |  | baseline | 
| Correlation of the patterns of expression of the translocation-specific transcripts with age, sex, race, response to treatment, survival, and with other known mutations |  | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adult acute myeloid leukemia in remission, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(8;21)(q22;q22), childhood acute myeloid leukemia in remission, recurrent adult acute myeloid leukemia, recurrent childhood acute myeloid leukemia, secondary acute myeloid leukemia, untreated adult acute myeloid leukemia, untreated childhood acute myeloid leukemia and other myeloid malignancies